SDGR Schrödinger
Physics-plus-AI molecular design software
Fundamentals from public market data, refreshed daily (2026-10-24 02:59 UTC). Figures in reporting currency.
SDGR · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-08-05EarningsBeat / raise
Reported EPS -0.42 vs -0.67 expected (+37.9% surprise).
-
7
2026-05-05EarningsMiss / cut
Reported EPS -0.62 vs -0.57 expected (-8.9% surprise).
-
6
2026-02-25EarningsMiss / cut
Reported EPS -0.18 vs -0.09 expected (-100.2% surprise).
-
5
2025-11-05EarningsBeat / raise
Reported EPS -0.57 vs -0.74 expected (+23.0% surprise).
-
4
2025-08-06EarningsMiss / cut
Reported EPS -0.65 vs -0.64 expected (-1.6% surprise).
-
3
2025-05-07EarningsBeat / raise
Reported EPS -0.64 vs -0.81 expected (+21.0% surprise).
-
2
2025-02-26EarningsBeat / raise
Reported EPS -0.24 vs -0.38 expected (+36.8% surprise).
-
1
2024-11-12EarningsMiss / cut
Reported EPS -0.87 vs -0.63 expected (-38.1% surprise).
Latest headlines
Auto-updated daily- Schrödinger to Announce Third Quarter 2026 Financial Results on November 42026-10-21
- Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry2026-10-14
- Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2026-09-17
- Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?2026-09-16
- Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs2026-09-09
- Schrödinger to Present at Morgan Stanley Global Healthcare Conference2026-09-01
- Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth2026-10-14
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.67 | -0.42 | +37.9% |
| 2026-05-05 | -0.57 | -0.62 | −8.9% |
| 2026-02-25 | -0.09 | -0.18 | −100.2% |
| 2025-11-05 | -0.74 | -0.57 | +23.0% |
| 2025-08-06 | -0.64 | -0.65 | −1.6% |
| 2025-05-07 | -0.81 | -0.64 | +21.0% |
| 2025-02-26 | -0.38 | -0.24 | +36.8% |
| 2024-11-12 | -0.63 | -0.87 | −38.1% |
| 2024-07-31 | -0.89 | -0.74 | +16.6% |
| 2024-05-01 | -0.74 | -0.76 | −2.7% |
| 2024-02-28 | -0.36 | -0.31 | +13.7% |
| 2023-11-01 | -0.69 | -0.7 | −1.4% |
| 2023-08-02 | -0.38 | -0.6 | −57.9% |
| 2023-05-04 | -0.19 | -0.23 | −22.9% |
| 2023-02-28 | -0.46 | -0.22 | +51.9% |
| 2022-11-03 | -0.59 | -0.5 | +16.0% |
| 2022-08-04 | -0.49 | -0.17 | +64.3% |
| 2022-05-04 | -0.43 | -0.27 | +37.4% |
| 2022-02-24 | -0.32 | -0.22 | +32.5% |
| 2021-11-10 | -0.29 | -0.38 | −30.2% |
| 2021-08-12 | -0.09 | -0.32 | −257.6% |
| 2021-05-11 | -0.25 | -0.27 | −6.8% |
| 2021-03-04 | -0.13 | -0.21 | −59.6% |
| 2020-11-12 | -0.09 | -0.22 | −128.2% |
About Schrödinger
Website ↗Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | AI drug discovery with NVIDIA-backed compute | $3.77 | +1.89% | +0.8% | −7.8% | |
| ABSI Absci | Generative-AI antibody design | $9.55 | +4.03% | −1.9% | +173.6% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $12.15 | +2.81% | −4.3% | +255.3% | |
| TEM Tempus AI | Clinical and genomic data for AI diagnostics | $66.46 | −1.71% | −21.8% | +12.6% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.